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Purpose: To compare the acute toxicities in radical treatment of prostate cancer between conventional schedule
(C-ARM) with 78 Gy/39 fractions and hypofractionation conformal treatment (H-ARM) with 69 Gy/23 fractions.
Methods and material: This prospective double arm study consisted of 217 patients with prostate cancer, 112 in
H-ARM and 105 in C-ARM arm. C-ARM received conventional six- field conformal radiotherapy with 78 Gy in 39
fractions while H-ARM received hypofractionation with 69 Gy in 23 fractions. Weekly assessment of acute reactions
was done during treatment and with one, and 3 months using RTOG scale. Univariated analysis was performed to
evaluate differences between the incidences of acute reaction in the treatment arms. Variables with p value less
than 0.1 were included in the multivariated logistic regression.
Results: There was no difference between H-ARM versus C-ARM for severity and incidence in genitourinary (GU)
and gastrointestinal (GI) acute toxicity. During the treatment comparing H-ARM with C-ARM no differences was
observed for GI toxicity (grade 0–3; H-ARM = 45.5%, 34%, 18.7% and 1.8% versus C-ARM = 47.6%, 35.2%, 17.2% and 0).
For acute GU toxicity no difference was detected between H-ARM (grade 0–3; 22.3%, 54.5%, 18.7% and 4.5%) and
C-ARM (grade 0–3; 25.8%, 53.3%, 17.1% and 3.8%).
At the 3- months follow-up, persistent Grade > =2 acute GU and GI toxicity were 2.5% and 1.8% in H-ARM versus 5.7%
and 3% in C-ARM (p > 0.05). In univariated and multivariated analyses, there was not any dosimetric predictor for GI
and GU toxicity.
Conclusions: Our data demonstrate that hypofractionated radiotherapy achieving high biological effective dose using
conformal radiotherapy is feasible for prostate cancer, being well tolerated with minimal severe acute toxicity.
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In the last decades, it has been shown that exists a
dose–response relation between the prostate cancer bio-
chemical control and the total dose of radiotherapy
delivered [1]. Evidences have also been growing from
experimental and clinical studies that the α/β ratio of
the linear-quadratic formulation for prostate cancer
might be between 1.5 and 1.85 Gy [2-4]. This low α/β
ratio suggests that prostate cancer has high sensitivity to* Correspondence: gusviani@gmail.com
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reproduction in any medium, provided the ordose per fraction, which suggests that a hypofractionation,
with a large radiation dose delivered in a smaller number
of fractions, might be more advantageous when compared
to other type of cancer cells. On the other hand, the α/β
ratio of the rectum is as important as that of prostate
cancer for exploring which hypofractionation regimens
will be most beneficial. Although α/β ratio for the rectal
wall is not known precisely, animal studies suggest α/β
ratio for the rectum of 4–6 G [5] . If the α/β ratio for rec-
tum is higher than that for prostate, theoretically, larger
hypofractionated doses could be given with larger clinical
gains within the same or lower complication rates [6].
Although the hypofractionation schedule for prostate can-
cer appears more attractive than conventional fractionation,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Dose constrains
Variables C-Arm H-Arm
PTV 95% of PTV78 to
receive 78 Gy
95% of PTV69 to
receive 69Gy
(by definition) (by definition)
Rectum V60 Gy < = 50% V50Gy < = 50%
V65 Gy < = 35% V54Gy < = 35%
V70Gy < = 25% V58Gy < =25%
V75Gy < = 15% V62Gy < = 15%
Bladder V65Gy < = 50% V54Gy < = 50%
V70Gy < = 35% V58Gy < = 35%
V75Gy < = 25% V62Gy < = 25%
V80Gy < = 15% V67Gy < = 15%
Femurs Maximal dose < = 55 Gy Maximal dose < = 46 Gy
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lent doses of 78–80 Gy has been limited.
These limited data are from a randomized Phase III
trial comparing a conventional fractionation regimen of
80 Gy given in 2-Gy fractions with a hypofractionation
regimen of 62 Gy given in 20 fractions of 3.1 Gy/d [7], a
nonrandomized study of hypofractionation vs. conven-
tional fractionation delivered using 3D conformal radio-
therapy technique [8], and a few other Phase I-II reports
using image guide radiotherapy (IGRT) or intensity-
modulated radiotherapy (IMRT) [9-11].
In order to compare two-fractionation regimens of radio-
therapy in prostate cancer patients, we compared a high
dose hypofractionation schedule (69 Gy/ 23 fractions)
with conventional fractionation (78 Gy/39 fractions).
This report summarizes the acute genitourinary and
gastrointestinal side effects for all patients included in
our prospective nonrandomized study, comparing con-
ventional or hypofractionated RT.
Material and methods
It is a prospective study conducted after the approval of the
institutional review board. The study population consisted
of 217 patients with localized prostate cancer, who were
treated between November 2009 and January 2011, with
patients selected into two arms. Patients in C-Arm received
conventional radiotherapy and those in H-Arm received
hypofractionated radiotherapy, both treatments with con-
formal technique.
Evaluation
The pretreatment evaluation consisted of a full history,
with special emphasis on pretreatment urinary and rectal
symptoms, and a physical examination. The prognostic
groups were defined as follows: low risk, Stage T1-T2a,
Gleason score <7, and initial prostate-specific antigen
(iPSA) level <10 ng/mL; intermediate risk, Stage T1-T2b,
Gleason score <7, and iPSA level of 10–19.9 ng/mL or
Stage T1-T2b, Gleason score 7, and iPSA <20 ng/mL; and
high risk, Stage T3, Gleason score 8–10, or iPSA >20 ng/mL.
Patients with metastases were excluded this trial.
Selection for treatment arms
Patients were selected for treatment arms according to
their convenience. This bias was permitted, because the
most patients came from long distances to treat. The
groups were balance to achieve similar distribution be-
tween the treatment arms. If a patient was chosen to be
treated in the H- Arm, the next patient automatically
was allocated in C-arm.
Treatment
For each patient, a conformal radiotherapy plan consisting
of six 6-MV photon beams was used to deliver 69 Gy in23 daily fractions of 3 Gy or 78 Gy in 39 fractions of 2 Gy,
prescribed at the isocenter. No patient was treated with
Intesity Modulated Radiotherapy (IMRT) and without any
fiducial. This dose was used because, according to the
linear quadratic formula, it is biologically equivalent to
87.8 Gy in 2 Gy fractions or 90 Gy in 50 fractions assum-
ing an α/β ratio of 1.8 and 1.5 Gy, respectively. All patients
underwent a treatment planning CT (5-mm slice thick-
ness) in the supine position with a triangle sponge placed
under their knees. Patients were advised to have a com-
fortably full bladder and an empty rectum at time of com-
puted tomography (CT) simulation. The prostate, seminal
vesicles base, whole rectum, bladder, femoral heads, and
penile bulb were contoured in all patients. The clinical tar-
get volume was the prostate plus seminal vesicles base; no
patient had the pelvis included in the clinical volume. The
planning target volume consisted of the clinical target
volume plus a uniform 10-mm margin in all directions,
excluding the rectal margin (7 mm). All fields were treated
daily. Single exposure portal films were obtained previous
to the first fraction and weekly thereafter. Dose–volume
histograms (DVHs) were calculated for a rectal volume
encompassing the organ from anal merge to the
retosigmoid transition. Rectal DVH constraints were
V60 Gy < = 50%, V65 Gy < = 35%, V 70Gy < = 25% and
V 75Gy < = 15% for C-Arm. In the H-Arm, DVHs were
calculated from the standard 2-Gy fractionation equiva-
lent to the doses of 3 Gy by fraction (assuming α/β = 3 Gy).
Table 1 describes the rectal and Bladder DVH con-
strains used in H-Arm and C-Arm. The software used
was Eclipse version 8.6, Varian Medical System, Inc,
Palo Alto, USA. Patients considered as intermediate or
high risk were treated with neoadjuvant, comcomitant
and adjuvant androgen blockage. The intermediate risk
received 6 months and high risk 24 months of andro-
gen blockage. The androgen blockage consisted of a
Table 2 Patients characteristics
Characteristic C-Arm Hypo-Arm P value
Patients (n) 105 112
Age (median) 72 71 0.913
Baseline Gleason score
>7 40 42 0.384
<=7 65 70 0.765
Initial PSA level (ng/mL)
Mean 8.6 9.2 0.682
Range 0.72- 58.4 0.59 – 62.8
Risk stratification
Low risk 38 35 0.424
Intermediate Risk 44 40 0.485
High Risk 40 30 0.827
Androgen treatment 84 70 0.938
Follow-up (mo) 3 months 3 months
Mean rectal volume (cm3) 60.8 + −2.9 59.7 + −2.7 0.512
Mean bladder volume (cm3) 262.0 + −16.5 258.9 + − 17.7 0.239
PTV Mean total volume (cm3) 167.5 + − 30.5 162.8 + − 31.2 0.114
Table 3 Incidence of maximum acute RTOG toxicity
during the treatment
Characteristic C-Arm Hypo-Arm P value
GI toxicity
Grade 0 50 (47.6) 51 (45.5) 0.643
Grade 1 37 (35.2) 38 (34) 0.521
Grade 2 18 (17.2) 21 (18.7) 0.235
Grade 3 0 2 (1.8) 0.573
GU toxicity
Grade 0 27 (25.8) 25 (22.3) 0.285
Grade 1 56 (53.3) 61 (54.5) 0.594
Grade 2 18 (17.1) 21 (18.7) 0.631
Grade 3 4 (3.8) 5 (4.5) 0.432
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of 3.6 mg.
End points
The primary study outcome was acute treatment reactions
from the beginning of treatment to 3 months after the
end of treatment. Patients were seen weekly, or as re-
quired, during treatment by a radiation oncologist. Pre-
existent urinary or rectal disorders, such as dysuria,
pollakiuria, stress incontinence, hemorrhoids, and so
forth, were assigned a grade complication if RT had exa-
cerbated the baseline dysfunction. Acute gastrointestinal
(GI) (retite, diarrhea, tenesmus and fecal incontinence)
and genitourinary (GU) toxicity (dysuria, urinary fre-
quency, retention, hematuria and urinary incontinence)
were prospectively assessed and graded according to the
Radiation Therapy Oncology Group scoring system for
the rectum and bladder.
Statistical analysis
The association between the two groups was determined
through bivariate analysis using Pearson’s chi square test
or Fisher test, when necessary. To compare continuous
variable the student T test was used. Two sided p value
was calculated and any difference with a p value < 0.05
was considered significant. The dosimetric parameters
such as; rectal, PTV and bladder volume were extracted
from the treatment plan as well as age and ADT. These
variables were tested whether they were related to the
probability of having > = Grade 2 RTOG toxicity.
Univariated analysis and multivariated logistic regression
were performed to evaluate differences between the inci-
dences of acute reaction in the treatment arms. All stat-
istical analysis was performed using SPSS (Statistical
Analysis Systems software), version 19.
Results
A total of 217 patients (112 H-Arm and 105 C-Arm)
treated on protocol from December 2009 to January
2011 were prospectively analyzed in this study. Baseline
characteristics for all patients are shown in Table 2. The
median age at last follow-up was 72 and 71 years for C-
Arm and H-Arm, respectively. The follow-up for all pa-
tients was 3 months. Acute toxicity was weakly assessed
during treatment and as needed by the patient before
the regular follow-up. The majority of the patients toler-
ated the treatment well without major acute GI or GU
side effects during the treatment (47.6% in C-Arm and
45.5% in H-arm for GI toxity and 25.8% in C-Arm
versus 22.3% H-Arm for GU toxicity), as described in
Table 3. The maximum acute GI and GU toxicities are
shown for the whole group and for each fractionation
schedule in Table 3. There was no apparent difference in
any acute toxicity when compared the H-Arm to theC-Arm (p >0.05). During the treatment there were 23% of
those in H-Arm and 19% in C - Arm taking medication to
improve urinary function (e.g., alpha blocker, antispas-
modic, analgesic such as Pyridium). At 3 months of follow
up, only 2 patients in H-Arm (1.8%) experiencing an
acute GI toxicity score of 2 or more. Otherwise, in C –
Arm 4 patients (3.8%) experienced an acute GI toxicity
score of 2, and 2 patients (1.9%) experienced an acute GU
toxicity score of 3. Three patients in each arm developed
acute GU toxicity Grade 3 (2.5% in H-arm and 3% in C-
arm), as seen in Table 4. With 3-month follow up there
were 15% and 13% in H-Arms and C-Arms taking medi-
cation to improve urinary function; the difference was not
significant.
Table 4 Maximum acute RTOG toxicity at 3 months of
follow up
Characteristic C-Arm (%) Hypo-Arm (%) P value
105 patients 112 patients
GI toxicity
Grade 0 86 (82) 94 (84) 0.945
Grade 1 13 (12.3) 16 (14.2) 0.221
Grade 2 4 (3.8) 1 (0.9) 0.578
Grade 3 2 (1.9) 1 (0.9) 0.683
GU toxicity
Grade 0 81 (77.1) 84 (75) 0.321
Grade 1 17 (16.1) 21 (19) 0.465
Grade 2 4 (3.8) 4 (3.5) 0.987
Grade 3 3 (3) 3 (2.5) 0.980
Table 6 The multivariate analysis (logistic regression)
evaluating the gastrointestinal or the genitourinary
toxicity > = grade 2
Gastrointestinal toxicity
Factor Relative Risk 95% CI P
Hypofractionation treatment 1.03 0.45 - 15.56 0.953
No ADT 0.87 0.27 - 15.72 0.956
Age > = 70 years 1.29 0.68 - 13.42 0.765
PTV volume > = 165 1.33 0.72 - 11.14 0.674
Rectal volume > = 60 0.98 0.38 - 7.55 0.998
Genitourinary toxicity
Hypofractionation treatment 1.17 0. 58–6.4 0.978
No ADT 1.09 0.52 – 15.65 0.743
Age > = 70 years 1.13 0.59 – 14.01 0.661
PTV volume > = 165 1.46 0.76 – 10.92 0.932
Bladder volume > = 260 0.77 0.18 – 6.92 0.839
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metric and clinical parameters such as; PTV volume, rec-
tal volume, Bladder volume, age and androgen deprivation
with acute GI and GU toxicity after 3 months of follow
up, as described in Table 5. In the multivariate logistic re-
gression no variable was associated with acute GI or GU
acute toxicity, as described in Table 6.
Discussion
The present trial is the first nonrandomized study to
compare a high-dose hypofractionated with convention-
ally fractionated schedule using conformal radiotherapyTable 5 Maximum acute toxicity during follow up and
clinical parameters
Characteristic Grade > =2 Acute GI toxicity P value
C-Arm (%) H-Arm (%)
ADT 8 (7.6) 13 (11.6) 0.103
No ADT 10 (9.5) 10 (8.9)
PTV volume > =165 11 (10.4) 11 (9.8) 0.234
PTV volume < 165 7 (6.6) 9 (8)
Rectal volume > = 60 9 (8.5) 11 (9.8) 0.545
Rectal volume < 60 9 (8.5) 12 (10.7)
Age > = 70 11 (10.4) 12 (10.7) 0.756
Age < 70 8 (7.6) 8 (7.1)
Grade > = 2 acute GU toxicity
ADT 10 (9.5) 12 (10.7) 0.645
No ADT 12 (11.4) 14 (12.5)
PTV volume > = 165 13 (12.3) 15 (13.3) 0.453
PTV volume < 165 9 (8.5) 12 (10.7)
Bladder volume > = 260 9 (8.5) 13 (11.6) 0.987
Bladder volume < 260 13 (12.3) 14 (12.5)
Age > =70 11 (10.4) 14 (12.5) 0.876
Age < 70 11 (10.4) 13 (11.6)for prostate cancer. This study was designed to test the
hypothesis that a high- dose hypofractionation regimen
is equivalent to a conventional fractionation scheme in
terms of acute GI and GU toxicity. This hypothesis was
determined from the assumption that the α/β ratio
would be 1.5–2 Gy for prostate cancer [3,4] and 10 and
3 Gy for early and slowly proliferating normal tissue,
respectively. With the delivery of the same equivalent
total dose to prostate tumors using a hypofractionation
regimen, the corresponding equivalent doses to normal
tissue would be lower. Therefore, with a slight prolonga-
tion of the shorter overall treatment time (from 4.5
weeks), both acute and late toxicity would be reduced
compared with that occurring after conventional
fractionation.
Based on this premise, this radiation protocol has been
used at our institute since 2009. It was also empirically
designed to provide acceptable biochemical control with
satisfactory levels of toxicity, being convenient for the
patients and with advantages to the hospital in terms of
time and resource management. To date, the dose used
in this trial is one of the highest BED delivered in a
hypofractionated external beam regimen, as demon-
strated in Table 7 [9,10,12-15]. Our results demonstrate
that 69 Gy delivered in 23 daily fractions over 4.5 weeks
is well tolerated using our RT technique and dose con-
straints, as seen in Table 7.
Moreover, the hypofractination schedule was quite
well tolerated with more than 45% of patients presenting
no acute GI toxicity during the treatment and at 3
months of follow up, only 2% of patients had residual
grade > = 2 toxicity. This data are comparable to other
hypofractionation cohorts with residual Grade > =2 GI
toxicity rates of 4–5%. The incidence of Grade 2 or
greater acute reactions reported in the present report for
Table 7 Overview of published clinical data on hypofractionation in prostate cancer
References Fractions Fraction size Total dose weeks NTD2 for α/β Acute toxicity
α/β = 1.5 α/β =3 α/β =10 GI (%) GU (%)
Livsey et al. [12] 6 6 36 3 77.1 64.8 48
Kupelian et al. [9] 28 2.5 70 5.5 80 77 72.9 19 15
Soete et al. [15] 16 3.5 56 4 80 72.8 63 38 39
Madsen et al. [10] 5 6.7 33.5 1 78.5 65 46.6 22 13
Pollack et al. [13] 26 2.7 70.2 5 84.2 80.5 74.3 18 48
Martin et al. [14] 20 3 60 4 77.1 72 65 12 25
FAMEMA trial (present study) 23 3 69 4.5 88.7 83 76 20.5% 23.2%
Abbreviations: GI = gastrointestinal;GU = genitourinary; NTD2 = Equivalent dose (Gy) for 2-Gy fractionation; BED = biological effective dose.
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urinary 20.9%), than other trials of dose escalation.
Acute toxicity has been addressed in several randomized
clinical trials of dose escalation using standard fraction-
ation. In a French trial [16], 30% of patients presented
with acute rectal reactions of Grade 2 or greater and
37% with urinary reactions of Grade 2 or greater in the
arm treated to a mean dose of 78.5 Gy. In another study
from The Netherlands [17], gastrointestinal complica-
tions of Grade 2 or greater were experienced by 51% of
patients in the 78-Gy arm and urinary complications of
Grade 2 or greater in 55%. Therefore, the use of five
fractions weekly, instead of three or four, with an overall
treatment time of 38 days for our hypofractionation regi-
men, have not increased the acute toxicity.
Another point that deserves attention is our margin
given to the planning target volume (PTV). Despite the
use of a larger posterior margin (7mm) given to the
PTV in our cohort, the rates of acute GI toxicity were
similar to Soete et al. [15] delivering 56 Gy in 16 frac-
tions of 3.5 Gy with 3 mm of margin. In their study was
reported 5% of Grade 2 acute GI toxicity with no Grade
3 toxicity. For us, this satisfactory level of acute toxicity
observed in our study can be result of an accurate treat-
ment planning and set up verification, associated with a
close attention to the dose–volume constraints for the
organs at risk (Table 1). Although, does not exist a con-
sensus on the optimal dosimetric parameters to be used
in clinical practice. Rectal and bladder constraints are
used to reduce the incidence of bladder and rectal tox-
icity. So, we speculate that although the dose–volume
histograms based on the initial planning CT may not
reflect the real dose received by the rectum because of
displacement of the prostate and rectum during and be-
tween treatments, the use of restrictive DVH can help to
maintain the acute toxicity rates in a satisfactory level.
In our univariated and multivariated analysis compar-
ing dosimetric and clinical variables (e.g., risk group des-
ignation, PTV volume, SV irradiation, or hormonal
therapy) between the two groups, no significant relation-
ship with acute GI or GU effects was observed. This canbe probably related to the large variability of bladder
and rectum volumes during and between the treatments.
This founds are in agreement with those of Pollack et al.
[13], who also did not observe a target volume or
normal tissue dose–volume dosimetric relationship with
either acute GI or GU toxicity, nor with group designa-
tion or use of hormonal therapy.
Conclusion
We present here our early outcomes for a high dose
hypofractionated conformal radiotherapy regime for the
treatment of prostate cancer. This study suggests that
hypofractionated dose-escalated radiotherapy using con-
formal radiotherapy in prostate cancer is feasible and
produces acceptable toxicity with the dose constraints
used. No difference in incidence or severity of acute
gastrointestinal and genitourinary toxicity was observed
when compared to conventional fractionation. Moreover,
the acute toxicity rates were comparable to those of other
dose escalation trials using standard or hypofractionated
schedules, being transient, with only 2 patients having
persistent Grade 2 or higher GI toxicity by 3 months
follow up.
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